Drug intelligence / Profile preview

Neltenexine

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

Neltenexine is a small molecule mucolytic agent and elastase inhibitor. It is chemically an amide derivative of ambroxol and thiophenecarboxylic acid. Its mechanism of action involves inhibition of elastase enzymes, which may help prevent pulmonary emphysema by reducing tissue damage in the lungs. It has been investigated primarily for respiratory diseases involving mucus hypersecretion and inflammation such as chronic obstructive pulmonary disease (COPD) and pulmonary emphysema. The drug was developed to improve mucus clearance and reduce lung tissue degradation through its anti-elastase activity.

Brand names: Alveoten
Other names: N-[2,4-dibromo-6-[[(4-hydroxycyclohexyl)amino]methyl]phenyl]thiophene-2-carboxamideNeltenexine (INN)

Targets

Elastase

Beyond the preview

Go deeper on Neltenexine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neltenexine.

Explore the full profile